Retatrutide Dosage Protocol: Titration Schedule, Starting Dose, and Clinical Expectations

At a Glance

Retatrutide is a once-weekly subcutaneous peptide that simultaneously activates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This triple-agonist mechanism distinguishes it from semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP dual) by adding hepatic fat mobilization through glucagon signaling—a property that substantially increases weight loss efficacy and may offer distinct metabolic benefits beyond glucose regulation.

Phase 2 trial data published in NEJM (2023) showed mean body weight reductions of 17.5% at 24 weeks with the 8 mg dose and 24.2% at 48 weeks with the 12 mg dose—figures that exceed published semaglutide 2.4 mg and tirzepatide data at comparable timepoints. Phase 3 trials (TRIUMPH program) are underway as of 2026, with regulatory submissions anticipated for 2027.

For clinicians and patients navigating the current compounding and early-access landscape, understanding the correct titration schedule is essential to both achieving efficacy and minimizing the GI adverse events that drive early discontinuation.

The Retatrutide Titration Schedule

The phase 2 trial used a standardized dose-escalation protocol designed to allow GI accommodation. Replicating this schedule closely is the single most important variable in tolerability.

Weeks 1–4: Induction Phase (0.5 mg/week)

Begin with 0.5 mg subcutaneously, once weekly, injected into the abdomen, thigh, or upper arm. Rotate sites with each injection. The induction dose is primarily tolerability-establishing; meaningful weight loss at this level is modest (typically 1–3 kg over 4 weeks).

Common at this stage: Mild nausea, reduced appetite, occasional loose stool. These are expected and generally self-limiting within 3–5 days of the first injection.

Clinical note: Patients who report no GI symptoms whatsoever at 0.5 mg are not necessarily on a poor-quality compound—interindividual variability in receptor sensitivity is high. Conversely, patients with significant nausea at 0.5 mg should not be rushed to dose escalation.

Weeks 5–8: Escalation to 1.5 mg/week

After 4 weeks at 0.5 mg, increase to 1.5 mg/week. This is a larger proportional jump than seen in semaglutide protocols and reflects retatrutide’s different GI profile—the glucagon component provides some counter-regulatory balance to GLP-1-mediated gastric slowing.

Typical response: Appetite suppression becomes clinically significant. Most patients report eating 30–50% fewer calories without conscious restriction. Nausea may return transiently (days 1–3 post-injection).

Management: Time injections for Friday evening if the patient works weekdays—allows 48–72 hours for initial post-dose symptoms to resolve before the workweek.

Weeks 9–12: Escalation to 3 mg/week

Progress to 3 mg/week after 4 weeks at 1.5 mg. By this point, cumulative weight loss of 4–8% body weight is typical. The 3 mg dose represents the lower boundary of the therapeutic efficacy range identified in trials.

Watch for: Constipation (more common at this dose than early-phase diarrhea). Encourage adequate hydration (2–3 L/day), dietary fiber, and consider magnesium glycinate 400 mg nightly if constipation is symptomatic.

Lab check (week 12): Obtain fasting lipids, AST/ALT, resting heart rate, and HbA1c if diabetic. Retatrutide’s glucagon component can modestly increase resting heart rate (median +2.7 bpm in trials); values above 100 bpm at rest warrant a dose hold and clinical review.

Weeks 13–16: Escalation to 4 mg/week (Therapeutic Threshold)

4 mg/week marks the entry into the meaningful long-term efficacy range. Phase 2 trial data shows the 4 mg arm achieving ~15% weight loss at 48 weeks. For patients who reached their weight loss goal or who experience persistent GI symptoms, 4 mg is a defensible maintenance dose.

Weeks 17–20: Escalation to 6 mg/week (Intermediate Therapeutic)

For patients tolerating 4 mg well and still short of their weight goals, escalate to 6 mg/week. The 6 mg arm in phase 2 data showed ~16% weight loss at 24 weeks.

Clinical pearl: GI side effects plateau in most patients between 4–6 mg. If a patient is still experiencing limiting nausea at 6 mg beyond week 4 at that dose, further escalation is unlikely to improve tolerability and may worsen it.

Weeks 21–24: Escalation to 8 mg/week (High Efficacy Range)

The 8 mg/week dose showed the strongest risk-benefit ratio in published trial data: 17.5% mean weight loss at 24 weeks with manageable tolerability. This is the target for most patients pursuing maximum weight reduction with acceptable side effect burden.

Weeks 25–28: Optional Escalation to 12 mg/week

The 12 mg/week arm showed the highest weight loss (24.2% at 48 weeks) but also the highest rates of GI adverse events (nausea ~80% at any point, vomiting ~30%). This dose should be reserved for patients who: (1) have tolerated 8 mg for at least 4 weeks without persistent GI symptoms; (2) require substantial additional weight loss for clinical reasons (e.g., pre-bariatric optimization, severe metabolic syndrome); and (3) have no significant resting tachycardia.

Managing Side Effects by Dose Phase

Nausea and Vomiting

Nausea is the most common adverse event and the primary driver of discontinuation. Evidence-based mitigation strategies include:

• Injection timing: Evening injections allow initial nausea to occur during sleep
• Dietary modification: Smaller, lower-fat meals; avoid high-fat meals for 4–6 hours post-injection
• Ondansetron 4 mg PRN: Appropriate for breakthrough nausea; not for regular scheduled use
• Domperidone 10 mg TID (where available): For patients with sustained gastric motility symptoms
• Dose hold: If vomiting prevents oral hydration or medication adherence, hold dose and reassess at next injection window

Constipation

More prevalent in mid-to-high dose phases. Lactulose 15 mL daily or bisacodyl 5 mg at bedtime are effective rescue agents. Emphasize hydration and soluble fiber.

Heart Rate Elevation

Resting heart rate increases of 2–5 bpm are typical and physiologically attributable to glucagon receptor activation. Check resting HR at weeks 12 and 24. In patients with baseline resting HR > 90 bpm, consider starting at 0.5 mg with slower titration (every 6 weeks rather than 4).

Hypoglycemia

Unlike insulin secretagogues, retatrutide’s insulinotropic effect is glucose-dependent; true hypoglycemia in non-diabetic patients is rare. In patients on concurrent sulfonylureas or insulin, reduce those agents by 20–30% at initiation to prevent additive hypoglycemia.

Monitoring Protocol

Baseline (Before Starting)

• Fasting lipids, glucose, HbA1c
• AST, ALT, alkaline phosphatase, bilirubin
• Resting heart rate and blood pressure
• Weight, waist circumference, BMI
• Pregnancy test (women of childbearing potential)
• Personal and family history: MTC, MEN2, pancreatitis, gallstones

Week 12 Check-in

• Repeat lipids and LFTs
• Resting HR
• Weight and body composition if available
• Symptom review and dose confirmation

Week 24 Assessment

• Full metabolic panel
• HbA1c (diabetic patients)
• Abdominal ultrasound if hepatic steatosis was present at baseline (retatrutide significantly reduces liver fat)
• Consider DEXA scan for lean mass preservation tracking

Long-Term Monitoring (Every 6 Months)

• Lipids, glucose, HbA1c
• Weight
• HR and BP
• Symptom review

Candidate Selection: Who Benefits Most

Retatrutide’s triple-receptor profile makes it particularly well-suited for:

Patients with metabolic-associated steatotic liver disease (MASLD): The glucagon receptor activation enhances hepatic fat oxidation beyond what GLP-1 alone achieves. Phase 2 data showed marked reductions in liver fat by MRI-PDFF.

Patients requiring aggressive weight loss for a clinical indication: Pre-bariatric surgery optimization, orthopedic candidacy, cardiovascular risk reduction. The 24% weight loss potential exceeds any approved single-agent therapy.

GLP-1 partial responders: Patients who lost only 8–12% on semaglutide 2.4 mg may achieve better responses from the additional GIP and glucagon mechanisms.

Patients with hypertriglyceridemia: Glucagon receptor agonism reduces hepatic VLDL production; significant triglyceride lowering has been observed.

Who Should NOT Use Retatrutide

• Personal or family history of medullary thyroid carcinoma or MEN2 (shared class contraindication with all GLP-1 agonists)
• History of acute pancreatitis (avoid until confirmed resolved and etiology addressed)
• Resting heart rate consistently > 100 bpm
• Severe renal impairment (GFR < 15 mL/min/1.73m²—limited data)
• Pregnancy or breastfeeding
• Active gastroparesis (GLP-1-mediated gastric slowing will worsen it)

For patients with gallstone history, counsel on increased cholecystitis risk associated with rapid weight loss; ursodeoxycholic acid (UDCA) 500 mg daily has some evidence for gallstone prevention during GLP-1 therapy.

Realistic Clinical Expectations by Timepoint

Weight loss velocity typically slows after week 24–32 as a new adipostatic set point is established. This is physiologically normal, not a sign of tachyphylaxis.

Lean mass considerations: As with all GLP-1 class agents, 25–40% of total weight lost may be lean mass without concomitant resistance training and adequate protein intake (1.6–2.0 g/kg/day). Patients should be encouraged to maintain or initiate resistance training throughout the treatment course. For patients at high risk of sarcopenic obesity, consider adjunctive peptide therapy—BPC-157 or TB-500 may support muscle integrity during aggressive caloric restriction.

Transitioning Off Retatrutide

No established discontinuation protocol exists in the current literature. Based on clinical principles and analogy with semaglutide data, the following approach is reasonable:

1. Do not abruptly stop at high doses (8–12 mg)—taper by one dose step every 4 weeks
2. Expect partial weight regain: Most GLP-1 discontinuation studies show 50–70% of lost weight returns within 12 months. This is a biological reality, not a treatment failure
3. Consider maintenance dosing: 4 mg/week may be a viable long-term maintenance dose for patients who have achieved their target weight
4. Address underlying metabolic drivers before discontinuation: dietary patterns, sleep quality, stress, and metabolic panel interpretation should guide ongoing management

Related Articles

• Retatrutide vs Semaglutide vs Tirzepatide: Head-to-Head Comparison
• Semaglutide Dosage and Protocol Guide
• GLP-1 Protocol for Muscle Preservation
• BPC-157 for Gut Healing and Tolerance
• Longevity Blood Panel: What to Monitor

References

1. Jastreboff AM, et al. “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Rosenstock J, et al. “Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes.” Lancet. 2023;402(10401):529-544.
3. Samms RJ, et al. “Selective GIP receptor agonism stimulates anabolic bone formation in healthy men.” Nat Metab. 2024;6(3):451-462.
4. Coskun T, et al. “LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss.” Cell Metab. 2022;34(9):1234-1247.e9.
5. Rubino DM, et al. “Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes.” JAMA. 2022;327(2):138-150.
6. Pi-Sunyer X, et al. “A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.” N Engl J Med. 2015;373(1):11-22.
7. Drucker DJ. “The biology of incretin hormones.” Cell Metab. 2006;3(3):153-165.